Zoetis in the news

Investor Michael Burry sold Flutter Entertainment, bought Lululemon Athletica under $100, and increased his stake in Zoetis Inc., citing valuation opportunities and potential management changes.

Zoetis stock has experienced significant declines following a reduced 2026 outlook and faces mixed investor sentiment regarding its valuation, growth prospects, and financial risks.

Discussions surrounding Michael Burry's portfolio inclusion of Zoetis highlight its stable demand despite recent growth moderation and a stock price drop, with mixed insider, congressional, and hedge fund activity alongside a median analyst price target of $99.0.

Zoetis Inc. stock performed poorly on Tuesday compared to its competitors.

Zoetis Inc. (NYSE: ZTS) shares dropped after an earnings revision and concerns over its canine arthritis product, Librela, impacting its performance in the Impax US Sustainable Economy Fund.

Zoetis's chief medical officer champions proactive animal healthcare, highlighting monoclonal antibodies' potential to revolutionize disease treatment, even amidst ongoing discussions about existing drug safety.

Zoetis appointed James Saccaro as the new CFO and COO, effective August 17, 2026, with current CFO Wetteny Joseph transitioning to an advisory role.

Two University of Missouri faculty members, Wenjun Ma and Tamara Hancock, received Zoetis awards for excellence in veterinary research and teaching, respectively.

Animal health leader Zoetis faces a stock price decline and class-action lawsuits following a Q1 earnings miss and concerns over prescription trends.

Zoetis faces a shareholder class action lawsuit following significant stock declines linked to weakened product demand and increased market competition.

Zoetis faces a class action lawsuit alleging it misled investors about the sales growth and safety concerns of its flagship animal health products.

faced recent stock sell-offs from institutional investors and legal challenges amid mixed Q1 financial results and lowered analyst price targets.

Animal health leader Zoetis faces a challenging period marked by earnings misses, securities fraud litigation, and mixed analyst ratings despite increased institutional investment.

Zoetis faces a stock price decline and securities-fraud litigation following a Q1 earnings miss and reduced institutional holdings.

Zoetis is dealing with a significant stock decline, legal challenges, and revenue drops in its US companion animal sector while analysts debate if the current share price reflects an undervaluation.

Analysts slashed price targets for Zoetis following a weak Q1 2026 update marked by declining U.S. pet care revenue and new class action lawsuits.

Zoetis stock declined recently but maintains positive monthly growth ahead of an expected earnings and revenue increase.

Zoetis Inc. stock underperformed compared to its competitors during Friday's trading session.

Zoetis leadership faces a derivative lawsuit for allegedly hiding safety concerns and misleading investors about pet medication risks.

Zoetis faces a securities fraud class action lawsuit following allegations of undisclosed market share losses and safety warnings for key canine health products.